Aclaris Therapeutics (ACRS) Shares Outstanding (Weighted Average) (2014 - 2026)

Aclaris Therapeutics' Shares Outstanding (Weighted Average) history runs 13 years deep, the most recent figure standing at $128.8 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 5.25% year-over-year to $128.8 million; the TTM figure through Mar 2026 stood at $128.8 million (up 5.25% YoY), while the FY2025 annual figure was $122.6 million, up 58.56% from the prior year.
• Shares Outstanding (Weighted Average) was $128.8 million for Q1 2026 at Aclaris Therapeutics, up from $122.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $128.8 million in Q1 2026 to a low of $61.4 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $84.7 million across 5 years, with a median of $71.1 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) increased 2.78% in 2024, then surged 72.21% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $65.2 million in 2022, then increased by 7.05% to $69.8 million in 2023, then advanced by 10.73% to $77.3 million in 2024, then surged by 58.56% to $122.6 million in 2025, then gained by 5.1% to $128.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $128.8 million (Q1 2026), $122.6 million (Q4 2025), and $122.5 million (Q3 2025), per Business Quant data.